- Home
- GALT vs RCS Comparison
GALT vs RCS Comparison
Compare GALT & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | RCS |
|---|---|---|
| Founded | 2000 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.0M | 246.0M |
| IPO Year | 2008 | 1994 |
Fundamental Metrics
Financial Performance| Metric | GALT | RCS |
|---|---|---|
| Price | $3.64 | $5.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 234.5K | 180.4K |
| Earning Date | 11-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.12% |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $4.84 |
| 52 Week High | $7.13 | $7.78 |
Technical Indicators
Market Signals| Indicator | GALT | RCS |
|---|---|---|
| Relative Strength Index (RSI) | 42.14 | 46.54 |
| Support Level | $3.58 | $4.87 |
| Resistance Level | $4.30 | $5.67 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 17.81 | 60.00 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About RCS PIMCO Strategic Income Fund Inc.
PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.